[A23-44] Luspatercept (myelodysplastic syndrome) – Benefit assessment according to §35a Social Code Book V
Last updated 15.08.2023
Project no.:
A23-44
Commission:
Commission awarded on 15.05.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Haematology
Adults with transfusion dependent anaemia due to very low, low and intermediate-risk MDS with ring sideroblasts, who had unsatisfactory response to or for whom erythropoetin-based therapy is ineligible.
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| G20-15 | Luspatercept (beta-thalassaemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V | Commission completed |
| G20-16 | Luspatercept (myelodysplastic syndromes) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V | Commission completed |
| A23-43 | Luspatercept (transfusion-dependent beta-thalassaemia) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A24-50 | Luspatercept (myelodysplastic syndromes) – Benefit assessment according to § 35a Social Code Book V | Commission completed |